Mitotane

Identification

Name

Mitotane

Accession Number

DB00648  (APRD00494)

Type

Small Molecule

Groups

Approved

Description

A derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. [PubChem]

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00648 (Mitotane)

×

Close

Synonyms

• Mitotan
• Mitotane
• Mitotano
• Mitotanum
• Piprine-DDD, O-

External IDs

CB 313 / NSC 38721

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Lysodren	Tablet	500 mg	Oral	Bristol Myers Squibb	1979-12-31	Not applicable
Lysodren	Tablet	500 mg/1	Oral	E.R. Squibb & Sons, L.L.C.	2009-06-01	Not applicable
Lysodren	Tablet	500 mg	Oral	Laboratoire HRA Pharma	2004-04-28	Not applicable

International/Other Brands

Lisodren (Bristol-Myers Squibb) / Lysodren / Opeprim (Yakult Honsha)

Categories

• Antineoplastic Agents
• Antineoplastic Agents, Hormonal
• Antineoplastic and Immunomodulating Agents
• Cytochrome P-450 CYP3A Inducers
• Cytochrome P-450 CYP3A Inducers (strong)
• Cytochrome P-450 CYP3A4 Inducers
• Cytochrome P-450 CYP3A4 Inducers (strong)
• Cytochrome P-450 Enzyme Inducers
• Hydrocarbons, Chlorinated
• Hydrocarbons, Halogenated
• P-glycoprotein/ABCB1 Inhibitors

UNII

78E4J5IB5J

CAS number

53-19-0

Weight

Average: 320.041
Monoisotopic: 317.953661148

Chemical Formula

C₁₄H₁₀Cl₄

InChI Key

JWBOIMRXGHLCPP-UHFFFAOYSA-N

InChI

InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

IUPAC Name

1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene

SMILES

ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl

Pharmacology

Indication

For treatment of inoperable adrenocortical tumours; Cushing's syndrome

Associated Conditions

• Cushing's Syndrome
• Inoperable Adrenocortical carcinoma

Pharmacodynamics

Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotane alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol.

Mechanism of action

Its biochemical mechanism of action is unknown, although data are available to suggest that the drug modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex.

Target	Actions	Organism
ACytochrome P450 11B1, mitochondrial	inducer	Human
UAdrenodoxin, mitochondrial	unknown	Human
UEstrogen receptor alpha	Not Available	Human
UProgesterone receptor	Not Available	Human
UAndrogen receptor	antagonist	Human

Absorption

About 40% oral Lysodren is absorbed

Volume of distribution

Not Available

Protein binding

6%

Metabolism

Hepatic and renal

Route of elimination

A variable amount of metabolite (1%-17%) is excreted in the bile and the balance is apparently stored in the tissues.

Half life

18-159 days

Clearance

Not Available

Toxicity

Not Available

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Mitotane.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane.	Experimental, Illicit
5-androstenedione	The serum concentration of 5-androstenedione can be decreased when it is combined with Mitotane.	Experimental, Illicit
Abemaciclib	The serum concentration of Abemaciclib can be decreased when it is combined with Mitotane.	Approved, Investigational
Abiraterone	The serum concentration of Abiraterone can be decreased when it is combined with Mitotane.	Approved
Acenocoumarol	The serum concentration of Acenocoumarol can be decreased when it is combined with Mitotane.	Approved, Investigational
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Mitotane.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Mitotane.	Approved
Acetyldigoxin	Acetyldigoxin may decrease the cardiotoxic activities of Mitotane.	Experimental
Adinazolam	The serum concentration of Adinazolam can be decreased when it is combined with Mitotane.	Approved
Agmatine	The serum concentration of Agmatine can be decreased when it is combined with Mitotane.	Experimental, Investigational
Albendazole	The serum concentration of Albendazole can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Alclometasone	The serum concentration of Alclometasone can be decreased when it is combined with Mitotane.	Approved
Aldosterone	The serum concentration of Aldosterone can be decreased when it is combined with Mitotane.	Experimental, Investigational
Alfentanil	The serum concentration of Alfentanil can be decreased when it is combined with Mitotane.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be decreased when it is combined with Mitotane.	Approved, Investigational
Aliskiren	The serum concentration of Aliskiren can be decreased when it is combined with Mitotane.	Approved, Investigational
Allylestrenol	The serum concentration of Allylestrenol can be decreased when it is combined with Mitotane.	Approved
Almotriptan	The serum concentration of Almotriptan can be decreased when it is combined with Mitotane.	Approved, Investigational
Alogliptin	The serum concentration of Alogliptin can be decreased when it is combined with Mitotane.	Approved
Alosetron	The serum concentration of Alosetron can be decreased when it is combined with Mitotane.	Approved, Withdrawn
alpha-Tocopherol acetate	The serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Mitotane.	Approved
Alprazolam	The serum concentration of Alprazolam can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Mitotane.	Approved, Investigational
Ambroxol	The serum concentration of Ambroxol can be decreased when it is combined with Mitotane.	Approved, Investigational
Amcinonide	The serum concentration of Amcinonide can be decreased when it is combined with Mitotane.	Approved
Aminophenazone	The serum concentration of Aminophenazone can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Mitotane.	Approved
Amiodarone	The serum concentration of Amiodarone can be decreased when it is combined with Mitotane.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Mitotane.	Approved
Amlodipine	The serum concentration of Amlodipine can be decreased when it is combined with Mitotane.	Approved
Amprenavir	The serum concentration of Amprenavir can be decreased when it is combined with Mitotane.	Approved, Investigational
Ancestim	The risk or severity of cytotoxicity can be increased when Ancestim is combined with Mitotane.	Approved, Investigational, Withdrawn
Androstenedione	The serum concentration of Androstenedione can be decreased when it is combined with Mitotane.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be decreased when it is combined with Mitotane.	Investigational
anecortave acetate	The serum concentration of anecortave acetate can be decreased when it is combined with Mitotane.	Investigational
Antipyrine	The serum concentration of Antipyrine can be decreased when it is combined with Mitotane.	Approved, Investigational
Apalutamide	The serum concentration of Apalutamide can be decreased when it is combined with Mitotane.	Approved, Investigational
Apixaban	The serum concentration of Apixaban can be decreased when it is combined with Mitotane.	Approved
Apremilast	The serum concentration of Apremilast can be decreased when it is combined with Mitotane.	Approved, Investigational
Aprepitant	The serum concentration of Aprepitant can be decreased when it is combined with Mitotane.	Approved, Investigational
Aranidipine	The serum concentration of Aranidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Argatroban	The serum concentration of Argatroban can be decreased when it is combined with Mitotane.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Artemether	The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Mitotane resulting in a loss in efficacy.	Approved
Artemether	The serum concentration of Artemether can be decreased when it is combined with Mitotane.	Approved
Asenapine	The serum concentration of Asenapine can be decreased when it is combined with Mitotane.	Approved
Astemizole	The serum concentration of Astemizole can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Asunaprevir	The serum concentration of Asunaprevir can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Atamestane	The serum concentration of Atamestane can be decreased when it is combined with Mitotane.	Investigational
Atazanavir	The serum concentration of Atazanavir can be decreased when it is combined with Mitotane.	Approved, Investigational
Atorvastatin	The serum concentration of Atorvastatin can be decreased when it is combined with Mitotane.	Approved
Avanafil	The serum concentration of Avanafil can be decreased when it is combined with Mitotane.	Approved
Avatrombopag	The serum concentration of Avatrombopag can be decreased when it is combined with Mitotane.	Approved, Investigational
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Azelastine	The serum concentration of Azelastine can be decreased when it is combined with Mitotane.	Approved
Azelnidipine	The serum concentration of Azelnidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Azithromycin	The serum concentration of Azithromycin can be decreased when it is combined with Mitotane.	Approved
Banoxantrone	The serum concentration of Banoxantrone can be decreased when it is combined with Mitotane.	Investigational
Baricitinib	The serum concentration of Baricitinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Barnidipine	The serum concentration of Barnidipine can be decreased when it is combined with Mitotane.	Approved
Beclomethasone dipropionate	The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Mitotane.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be decreased when it is combined with Mitotane.	Approved
Bencyclane	The serum concentration of Bencyclane can be decreased when it is combined with Mitotane.	Experimental
Benidipine	The serum concentration of Benidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Benzphetamine	The serum concentration of Benzphetamine can be decreased when it is combined with Mitotane.	Approved, Illicit
Benzyl alcohol	The serum concentration of Benzyl alcohol can be decreased when it is combined with Mitotane.	Approved
Bepridil	The serum concentration of Bepridil can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Mitotane.	Approved, Investigational
Bexarotene	The serum concentration of Bexarotene can be decreased when it is combined with Mitotane.	Approved, Investigational
Bezafibrate	The serum concentration of Bezafibrate can be decreased when it is combined with Mitotane.	Approved, Investigational
Bicalutamide	The serum concentration of Bicalutamide can be decreased when it is combined with Mitotane.	Approved
Bictegravir	The serum concentration of Bictegravir can be decreased when it is combined with Mitotane.	Approved, Investigational
Bioallethrin	The serum concentration of Bioallethrin can be decreased when it is combined with Mitotane.	Approved, Experimental
Bisoprolol	The serum concentration of Bisoprolol can be decreased when it is combined with Mitotane.	Approved
Blonanserin	The serum concentration of Blonanserin can be decreased when it is combined with Mitotane.	Approved, Investigational
Boceprevir	The serum concentration of Boceprevir can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Bortezomib	The serum concentration of Bortezomib can be decreased when it is combined with Mitotane.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be decreased when it is combined with Mitotane.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Mitotane.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitotane.	Approved, Investigational
Brexpiprazole	The serum concentration of Brexpiprazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Brigatinib	The serum concentration of Brigatinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Brinzolamide	The serum concentration of Brinzolamide can be decreased when it is combined with Mitotane.	Approved
Brivaracetam	The serum concentration of Brivaracetam can be decreased when it is combined with Mitotane.	Approved, Investigational
Bromazepam	The serum concentration of Bromazepam can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Mitotane.	Approved, Investigational
Brompheniramine	The serum concentration of Brompheniramine can be decreased when it is combined with Mitotane.	Approved
Budesonide	The serum concentration of Budesonide can be decreased when it is combined with Mitotane.	Approved
Bupivacaine	The serum concentration of Bupivacaine can be decreased when it is combined with Mitotane.	Approved, Investigational
Buprenorphine	The serum concentration of Buprenorphine can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of Bupropion can be decreased when it is combined with Mitotane.	Approved
Buspirone	The serum concentration of Buspirone can be decreased when it is combined with Mitotane.	Approved, Investigational
Busulfan	The serum concentration of Busulfan can be decreased when it is combined with Mitotane.	Approved, Investigational
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Mitotane.	Approved
Cabergoline	The serum concentration of Cabergoline can be decreased when it is combined with Mitotane.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Mitotane.	Approved
Calcitriol	The serum concentration of Calcitriol can be decreased when it is combined with Mitotane.	Approved, Nutraceutical
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Mitotane.	Approved
Cannabidiol	The serum concentration of Cannabidiol can be decreased when it is combined with Mitotane.	Approved, Investigational
Carbamazepine	The serum concentration of Carbamazepine can be decreased when it is combined with Mitotane.	Approved, Investigational
Carbinoxamine	The serum concentration of Carbinoxamine can be decreased when it is combined with Mitotane.	Approved
Carboxyamidotriazole	The serum concentration of Carboxyamidotriazole can be decreased when it is combined with Mitotane.	Investigational
Cariprazine	The serum concentration of Cariprazine can be decreased when it is combined with Mitotane.	Approved, Investigational
Caroverine	The serum concentration of Caroverine can be decreased when it is combined with Mitotane.	Experimental
Carvedilol	The serum concentration of Carvedilol can be decreased when it is combined with Mitotane.	Approved, Investigational
Celecoxib	The serum concentration of Celecoxib can be decreased when it is combined with Mitotane.	Approved, Investigational
Celiprolol	The serum concentration of Celiprolol can be decreased when it is combined with Mitotane.	Approved, Investigational
Cephalexin	The serum concentration of Cephalexin can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be decreased when it is combined with Mitotane.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Cevimeline	The serum concentration of Cevimeline can be decreased when it is combined with Mitotane.	Approved
Chenodeoxycholic acid	The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Mitotane.	Approved
Chlordiazepoxide	The serum concentration of Chlordiazepoxide can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Chloroquine	The serum concentration of Chloroquine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Chlorphenamine	The serum concentration of Chlorphenamine can be decreased when it is combined with Mitotane.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Chlorzoxazone	The serum concentration of Chlorzoxazone can be decreased when it is combined with Mitotane.	Approved
Cholecalciferol	The serum concentration of Cholecalciferol can be decreased when it is combined with Mitotane.	Approved, Nutraceutical
Ciclesonide	The serum concentration of Ciclesonide can be decreased when it is combined with Mitotane.	Approved, Investigational
Cilnidipine	The serum concentration of Cilnidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Cilostazol	The serum concentration of Cilostazol can be decreased when it is combined with Mitotane.	Approved, Investigational
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Mitotane.	Approved, Investigational
Cinacalcet	The serum concentration of Cinacalcet can be decreased when it is combined with Mitotane.	Approved
Cinnarizine	The serum concentration of Cinnarizine can be decreased when it is combined with Mitotane.	Approved, Investigational
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Mitotane.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Citalopram can be decreased when it is combined with Mitotane.	Approved
Clarithromycin	The serum concentration of Clarithromycin can be decreased when it is combined with Mitotane.	Approved
Clevidipine	The serum concentration of Clevidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Clindamycin	The serum concentration of Clindamycin can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Mitotane.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be decreased when it is combined with Mitotane.	Approved, Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be decreased when it is combined with Mitotane.	Approved
Clobetasone	The serum concentration of Clobetasone can be decreased when it is combined with Mitotane.	Approved
Clocortolone	The serum concentration of Clocortolone can be decreased when it is combined with Mitotane.	Approved
Clofazimine	The serum concentration of Clofazimine can be decreased when it is combined with Mitotane.	Approved, Investigational
Clofibrate	The serum concentration of Clofibrate can be decreased when it is combined with Mitotane.	Approved, Investigational
clomethiazole	The serum concentration of clomethiazole can be decreased when it is combined with Mitotane.	Investigational
Clomipramine	The serum concentration of Clomipramine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Clonazepam	The serum concentration of Clonazepam can be decreased when it is combined with Mitotane.	Approved, Illicit
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Mitotane.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Mitotane.	Approved
Clorazepate	The serum concentration of Clorazepate can be decreased when it is combined with Mitotane.	Approved, Illicit
Clotiazepam	The serum concentration of Clotiazepam can be decreased when it is combined with Mitotane.	Approved, Illicit
Clozapine	The serum concentration of Clozapine can be decreased when it is combined with Mitotane.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Cocaine	The serum concentration of Cocaine can be decreased when it is combined with Mitotane.	Approved, Illicit
Codeine	The serum concentration of Codeine can be decreased when it is combined with Mitotane.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be decreased when it is combined with Mitotane.	Approved
Conivaptan	The serum concentration of Conivaptan can be decreased when it is combined with Mitotane.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated estrogens can be decreased when it is combined with Mitotane.	Approved
Copanlisib	The serum concentration of Copanlisib can be decreased when it is combined with Mitotane.	Approved, Investigational
Cortexolone 17α-propionate	The serum concentration of Cortexolone 17α-propionate can be decreased when it is combined with Mitotane.	Investigational
Corticosterone	The serum concentration of Corticosterone can be decreased when it is combined with Mitotane.	Experimental
Cortisone acetate	The serum concentration of Cortisone acetate can be decreased when it is combined with Mitotane.	Approved, Investigational
Crizotinib	The serum concentration of Crizotinib can be decreased when it is combined with Mitotane.	Approved
Cyclandelate	The serum concentration of Cyclandelate can be decreased when it is combined with Mitotane.	Approved
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane.	Approved
Cyclophosphamide	The serum concentration of Cyclophosphamide can be decreased when it is combined with Mitotane.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Cymarin	Cymarin may decrease the cardiotoxic activities of Mitotane.	Experimental
Cytarabine	The serum concentration of Cytarabine can be decreased when it is combined with Mitotane.	Approved, Investigational
Dabrafenib	The serum concentration of Dabrafenib can be decreased when it is combined with Mitotane.	Approved, Investigational
Daclatasvir	The serum concentration of Daclatasvir can be decreased when it is combined with Mitotane.	Approved, Investigational
Dantrolene	The serum concentration of Dantrolene can be decreased when it is combined with Mitotane.	Approved, Investigational
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Mitotane.	Approved
Dapsone	The serum concentration of Dapsone can be decreased when it is combined with Mitotane.	Approved, Investigational
Darifenacin	The serum concentration of Darifenacin can be decreased when it is combined with Mitotane.	Approved, Investigational
Darodipine	The serum concentration of Darodipine can be decreased when it is combined with Mitotane.	Experimental
Darunavir	The serum concentration of Darunavir can be decreased when it is combined with Mitotane.	Approved
Dasabuvir	The serum concentration of Dasabuvir can be decreased when it is combined with Mitotane.	Approved
Dasatinib	The serum concentration of Dasatinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be decreased when it is combined with Mitotane.	Approved
Deflazacort	The serum concentration of Deflazacort can be decreased when it is combined with Mitotane.	Approved, Investigational
Delamanid	The serum concentration of Delamanid can be decreased when it is combined with Mitotane.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Mitotane.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Mitotane.	Approved
Desonide	The serum concentration of Desonide can be decreased when it is combined with Mitotane.	Approved, Investigational
Desoximetasone	The serum concentration of Desoximetasone can be decreased when it is combined with Mitotane.	Approved
Desoxycorticosterone acetate	The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Mitotane.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Mitotane.	Experimental, Vet Approved
Desvenlafaxine	The serum concentration of Desvenlafaxine can be decreased when it is combined with Mitotane.	Approved, Investigational
Deutetrabenazine	The serum concentration of Deutetrabenazine can be decreased when it is combined with Mitotane.	Approved, Investigational
Dexamethasone	The serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Mitotane.	Vet Approved
Dexchlorpheniramine maleate	The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Mitotane.	Approved
Dexlansoprazole	The serum concentration of Dexlansoprazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Dexniguldipine	The serum concentration of Dexniguldipine can be decreased when it is combined with Mitotane.	Experimental
Dextromethorphan	The serum concentration of Dextromethorphan can be decreased when it is combined with Mitotane.	Approved
Dextropropoxyphene	The serum concentration of Dextropropoxyphene can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational, Withdrawn
Dexverapamil	The serum concentration of Dexverapamil can be decreased when it is combined with Mitotane.	Experimental
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational, Vet Approved
Diclofenac	The serum concentration of Diclofenac can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Mitotane.	Approved
Diflorasone	The serum concentration of Diflorasone can be decreased when it is combined with Mitotane.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Difluprednate	The serum concentration of Difluprednate can be decreased when it is combined with Mitotane.	Approved
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Mitotane.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be decreased when it is combined with Mitotane.	Approved
Digoxin Immune Fab (Ovine)	Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitotane.	Approved
Dihydro-alpha-ergocryptine	The serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Mitotane.	Approved
Dihydrocodeine	The serum concentration of Dihydrocodeine can be decreased when it is combined with Mitotane.	Approved, Illicit
Dihydroergotamine	The serum concentration of Dihydroergotamine can be decreased when it is combined with Mitotane.	Approved, Investigational
Diltiazem	The serum concentration of Diltiazem can be decreased when it is combined with Mitotane.	Approved, Investigational
Disopyramide	The serum concentration of Disopyramide can be decreased when it is combined with Mitotane.	Approved
Disulfiram	The serum concentration of Disulfiram can be decreased when it is combined with Mitotane.	Approved
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Mitotane.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be decreased when it is combined with Mitotane.	Approved, Investigational
Dolasetron	The serum concentration of Dolasetron can be decreased when it is combined with Mitotane.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Donepezil	The serum concentration of Donepezil can be decreased when it is combined with Mitotane.	Approved
Dorzolamide	The serum concentration of Dorzolamide can be decreased when it is combined with Mitotane.	Approved
Dotarizine	The serum concentration of Dotarizine can be decreased when it is combined with Mitotane.	Investigational
Doxepin	The serum concentration of Doxepin can be decreased when it is combined with Mitotane.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Mitotane.	Approved, Investigational
Dronabinol	The serum concentration of Dronabinol can be decreased when it is combined with Mitotane.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be decreased when it is combined with Mitotane.	Approved
Dutasteride	The serum concentration of Dutasteride can be decreased when it is combined with Mitotane.	Approved, Investigational
Efavirenz	The serum concentration of Efavirenz can be decreased when it is combined with Mitotane.	Approved, Investigational
Efonidipine	The serum concentration of Efonidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Elbasvir	The serum concentration of Elbasvir can be decreased when it is combined with Mitotane.	Approved
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Mitotane.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be decreased when it is combined with Mitotane.	Approved
Elvitegravir	The serum concentration of Elvitegravir can be decreased when it is combined with Mitotane.	Approved
Emopamil	The serum concentration of Emopamil can be decreased when it is combined with Mitotane.	Experimental
Enalapril	The serum concentration of Enalapril can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Enasidenib	The serum concentration of Enasidenib can be decreased when it is combined with Mitotane.	Approved, Investigational
Enzalutamide	The serum concentration of Enzalutamide can be decreased when it is combined with Mitotane.	Approved
Eperisone	The serum concentration of Eperisone can be decreased when it is combined with Mitotane.	Approved, Investigational
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Mitotane.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be decreased when it is combined with Mitotane.	Approved
Equilenin	The serum concentration of Equilenin can be decreased when it is combined with Mitotane.	Experimental
Equilin	The serum concentration of Equilin can be decreased when it is combined with Mitotane.	Approved
Ergocalciferol	The serum concentration of Ergocalciferol can be decreased when it is combined with Mitotane.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane.	Approved
Ergonovine	The serum concentration of Ergonovine can be decreased when it is combined with Mitotane.	Approved
Ergotamine	The serum concentration of Ergotamine can be decreased when it is combined with Mitotane.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Escitalopram	The serum concentration of Escitalopram can be decreased when it is combined with Mitotane.	Approved, Investigational
Esomeprazole	The serum concentration of Esomeprazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be decreased when it is combined with Mitotane.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Estradiol acetate	The serum concentration of Estradiol acetate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Estradiol benzoate	The serum concentration of Estradiol benzoate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Estradiol cypionate	The serum concentration of Estradiol cypionate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The serum concentration of Estradiol dienanthate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Estradiol valerate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Mitotane.	Approved, Investigational
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Mitotane.	Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Mitotane.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Mitotane.	Approved
Eszopiclone	The serum concentration of Eszopiclone can be decreased when it is combined with Mitotane.	Approved, Investigational
Ethanol	The serum concentration of Ethanol can be decreased when it is combined with Mitotane.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitotane.	Approved
Ethosuximide	The serum concentration of Ethosuximide can be decreased when it is combined with Mitotane.	Approved
Ethylmorphine	The serum concentration of Ethylmorphine can be decreased when it is combined with Mitotane.	Approved, Illicit
Etizolam	The serum concentration of Etizolam can be decreased when it is combined with Mitotane.	Approved
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Mitotane.	Approved, Investigational
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Mitotane.	Approved
Etoricoxib	The serum concentration of Etoricoxib can be decreased when it is combined with Mitotane.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Mitotane.	Approved
Everolimus	The serum concentration of Everolimus can be decreased when it is combined with Mitotane.	Approved
Exemestane	The serum concentration of Exemestane can be decreased when it is combined with Mitotane.	Approved, Investigational
Famciclovir	The serum concentration of Famciclovir can be decreased when it is combined with Mitotane.	Approved, Investigational
Felbamate	The serum concentration of Felbamate can be decreased when it is combined with Mitotane.	Approved
Felodipine	The serum concentration of Felodipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Fendiline	The serum concentration of Fendiline can be decreased when it is combined with Mitotane.	Withdrawn
Fenofibrate	The serum concentration of Fenofibrate can be decreased when it is combined with Mitotane.	Approved
Fentanyl	The serum concentration of Fentanyl can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Mitotane.	Approved
Finasteride	The serum concentration of Finasteride can be decreased when it is combined with Mitotane.	Approved
Fingolimod	The serum concentration of Fingolimod can be decreased when it is combined with Mitotane.	Approved, Investigational
Fish oil	The serum concentration of Fish oil can be decreased when it is combined with Mitotane.	Approved, Nutraceutical
Flibanserin	The serum concentration of Flibanserin can be decreased when it is combined with Mitotane.	Approved, Investigational
Fluasterone	The serum concentration of Fluasterone can be decreased when it is combined with Mitotane.	Investigational
Fludrocortisone	The serum concentration of Fludrocortisone can be decreased when it is combined with Mitotane.	Approved, Investigational
Flumethasone	The serum concentration of Flumethasone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Flunarizine	The serum concentration of Flunarizine can be decreased when it is combined with Mitotane.	Approved
Flunisolide	The serum concentration of Flunisolide can be decreased when it is combined with Mitotane.	Approved, Investigational
Flunitrazepam	The serum concentration of Flunitrazepam can be decreased when it is combined with Mitotane.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be decreased when it is combined with Mitotane.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Fluorometholone	The serum concentration of Fluorometholone can be decreased when it is combined with Mitotane.	Approved, Investigational
Fluoxetine	The serum concentration of Fluoxetine can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Fluprednidene	The serum concentration of Fluprednidene can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Fluprednisolone	The serum concentration of Fluprednisolone can be decreased when it is combined with Mitotane.	Approved
Flurandrenolide	The serum concentration of Flurandrenolide can be decreased when it is combined with Mitotane.	Approved
Flurazepam	The serum concentration of Flurazepam can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Fluspirilene	The serum concentration of Fluspirilene can be decreased when it is combined with Mitotane.	Approved, Investigational
Flutamide	The serum concentration of Flutamide can be decreased when it is combined with Mitotane.	Approved, Investigational
Fluticasone	The serum concentration of Fluticasone can be decreased when it is combined with Mitotane.	Approved, Experimental, Investigational
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Mitotane.	Approved
Fluticasone propionate	The serum concentration of Fluticasone propionate can be decreased when it is combined with Mitotane.	Approved
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Mitotane.	Approved
Formestane	The serum concentration of Formestane can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Fosamprenavir	The serum concentration of Fosamprenavir can be decreased when it is combined with Mitotane.	Approved
Fosnetupitant	The serum concentration of Fosnetupitant can be decreased when it is combined with Mitotane.	Approved
Fostamatinib	The serum concentration of Fostamatinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Fulvestrant	The serum concentration of Fulvestrant can be decreased when it is combined with Mitotane.	Approved, Investigational
Gabapentin	The serum concentration of Gabapentin can be decreased when it is combined with Mitotane.	Approved, Investigational
Galantamine	The serum concentration of Galantamine can be decreased when it is combined with Mitotane.	Approved
Gallopamil	The serum concentration of Gallopamil can be decreased when it is combined with Mitotane.	Investigational
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Gemfibrozil	The serum concentration of Gemfibrozil can be decreased when it is combined with Mitotane.	Approved
Gitoformate	Gitoformate may decrease the cardiotoxic activities of Mitotane.	Experimental
Glipizide	The serum concentration of Glipizide can be decreased when it is combined with Mitotane.	Approved, Investigational
Glyburide	The serum concentration of Glyburide can be decreased when it is combined with Mitotane.	Approved
Granisetron	The serum concentration of Granisetron can be decreased when it is combined with Mitotane.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Mitotane.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Guanfacine	The serum concentration of Guanfacine can be decreased when it is combined with Mitotane.	Approved, Investigational
Halcinonide	The serum concentration of Halcinonide can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be decreased when it is combined with Mitotane.	Approved
Haloperidol	The serum concentration of Haloperidol can be decreased when it is combined with Mitotane.	Approved
Halothane	The serum concentration of Halothane can be decreased when it is combined with Mitotane.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be decreased when it is combined with Mitotane.	Investigational
Hexobarbital	The serum concentration of Hexobarbital can be decreased when it is combined with Mitotane.	Approved
Histamine	The serum concentration of Histamine can be decreased when it is combined with Mitotane.	Approved, Investigational
Hydrocodone	The serum concentration of Hydrocodone can be decreased when it is combined with Mitotane.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Hydrocortisone acetate	The serum concentration of Hydrocortisone acetate can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Hydrocortisone butyrate	The serum concentration of Hydrocortisone butyrate can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Hydromorphone	The serum concentration of Hydromorphone can be decreased when it is combined with Mitotane.	Approved, Illicit
Hydroxyprogesterone caproate	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Mitotane.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be decreased when it is combined with Mitotane.	Approved
Icotinib	The serum concentration of Icotinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Idelalisib	The serum concentration of Idelalisib can be decreased when it is combined with Mitotane.	Approved
Ifosfamide	The serum concentration of Ifosfamide can be decreased when it is combined with Mitotane.	Approved
Iloperidone	The serum concentration of Iloperidone can be decreased when it is combined with Mitotane.	Approved
Imatinib	The serum concentration of Imatinib can be decreased when it is combined with Mitotane.	Approved
Imidafenacin	The serum concentration of Imidafenacin can be decreased when it is combined with Mitotane.	Approved, Investigational
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Mitotane.	Approved
Imiquimod	The serum concentration of Imiquimod can be decreased when it is combined with Mitotane.	Approved, Investigational
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Mitotane.	Approved
Indapamide	The serum concentration of Indapamide can be decreased when it is combined with Mitotane.	Approved
Indinavir	The serum concentration of Indinavir can be decreased when it is combined with Mitotane.	Approved
Ipecac	The serum concentration of Ipecac can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Ipratropium	The serum concentration of Ipratropium can be decreased when it is combined with Mitotane.	Approved
Irinotecan	The serum concentration of Irinotecan can be decreased when it is combined with Mitotane.	Approved, Investigational
Isavuconazole	The serum concentration of Isavuconazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Mitotane resulting in a loss in efficacy.	Approved, Investigational
Isosorbide Dinitrate	The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Mitotane.	Approved, Investigational
Isosorbide Mononitrate	The serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Mitotane.	Approved
Isradipine	The serum concentration of Isradipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Istaroxime	The serum concentration of Istaroxime can be decreased when it is combined with Mitotane.	Investigational
Itraconazole	The serum concentration of Itraconazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be decreased when it is combined with Mitotane.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be decreased when it is combined with Mitotane.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be decreased when it is combined with Mitotane.	Approved, Investigational
Ixazomib	The serum concentration of Ixazomib can be decreased when it is combined with Mitotane.	Approved, Investigational
Ketamine	The serum concentration of Ketamine can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Mitotane.	Approved
Ketobemidone	The serum concentration of Ketobemidone can be decreased when it is combined with Mitotane.	Approved, Investigational
Ketoconazole	The serum concentration of Ketoconazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Lacidipine	The serum concentration of Lacidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Mitotane.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Mitotane.	Approved, Investigational
Lanatoside C	Lanatoside C may decrease the cardiotoxic activities of Mitotane.	Experimental
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Laquinimod	The serum concentration of Laquinimod can be decreased when it is combined with Mitotane.	Investigational
Lenvatinib	The serum concentration of Lenvatinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Lercanidipine	The serum concentration of Lercanidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Letermovir	The serum concentration of Mitotane can be increased when it is combined with Letermovir.	Approved, Investigational
Letrozole	The serum concentration of Letrozole can be decreased when it is combined with Mitotane.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Mitotane.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be decreased when it is combined with Mitotane.	Approved, Investigational
Levocetirizine	The serum concentration of Levocetirizine can be decreased when it is combined with Mitotane.	Approved
Levomethadyl Acetate	The serum concentration of Levomethadyl Acetate can be decreased when it is combined with Mitotane.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be decreased when it is combined with Mitotane.	Approved, Investigational
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Mitotane.	Approved, Investigational
Levothyroxine	The serum concentration of Levothyroxine can be decreased when it is combined with Mitotane.	Approved
Lidocaine	The serum concentration of Lidocaine can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Lidoflazine	The serum concentration of Lidoflazine can be decreased when it is combined with Mitotane.	Experimental
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Mitotane.	Approved
Lisuride	The serum concentration of Lisuride can be decreased when it is combined with Mitotane.	Approved, Investigational
Lomerizine	The serum concentration of Lomerizine can be decreased when it is combined with Mitotane.	Experimental
Lomitapide	The serum concentration of Lomitapide can be decreased when it is combined with Mitotane.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Mitotane.	Approved
Lopinavir	The serum concentration of Lopinavir can be decreased when it is combined with Mitotane.	Approved
Loratadine	The serum concentration of Loratadine can be decreased when it is combined with Mitotane.	Approved, Investigational
Lorcaserin	The serum concentration of Lorcaserin can be decreased when it is combined with Mitotane.	Approved
Lorpiprazole	The serum concentration of Lorpiprazole can be decreased when it is combined with Mitotane.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Mitotane.	Approved
Loteprednol	The serum concentration of Loteprednol can be decreased when it is combined with Mitotane.	Approved
Lovastatin	The serum concentration of Lovastatin can be decreased when it is combined with Mitotane.	Approved, Investigational
Lumefantrine	The serum concentration of Lumefantrine can be decreased when it is combined with Mitotane.	Approved
Lurasidone	The serum concentration of Lurasidone can be decreased when it is combined with Mitotane.	Approved, Investigational
Macimorelin	The serum concentration of Macimorelin can be decreased when it is combined with Mitotane.	Approved, Investigational
Macitentan	The serum concentration of Macitentan can be decreased when it is combined with Mitotane.	Approved
Magnesium sulfate	The serum concentration of Magnesium sulfate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Manidipine	The serum concentration of Manidipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Maraviroc	The serum concentration of Maraviroc can be decreased when it is combined with Mitotane.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be decreased when it is combined with Mitotane.	Investigational
Mebendazole	The serum concentration of Mebendazole can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Medical Cannabis	The serum concentration of Medical Cannabis can be decreased when it is combined with Mitotane.	Experimental, Investigational
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mitotane.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be decreased when it is combined with Mitotane.	Approved
Mefloquine	The serum concentration of Mefloquine can be decreased when it is combined with Mitotane.	Approved, Investigational
Melengestrol	The serum concentration of Melengestrol can be decreased when it is combined with Mitotane.	Vet Approved
Meloxicam	The serum concentration of Meloxicam can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Menthol	The serum concentration of Menthol can be decreased when it is combined with Mitotane.	Approved
Methadone	The serum concentration of Methadone can be decreased when it is combined with Mitotane.	Approved
Methaqualone	The serum concentration of Methaqualone can be decreased when it is combined with Mitotane.	Illicit, Withdrawn
Methoxsalen	The serum concentration of Methoxsalen can be decreased when it is combined with Mitotane.	Approved
Methoxyflurane	The serum concentration of Methoxyflurane can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Methyltestosterone	The serum concentration of Methyltestosterone can be decreased when it is combined with Mitotane.	Approved
Metildigoxin	Metildigoxin may decrease the cardiotoxic activities of Mitotane.	Experimental
Metronidazole	The serum concentration of Metronidazole can be decreased when it is combined with Mitotane.	Approved
Mexiletine	The serum concentration of Mexiletine can be decreased when it is combined with Mitotane.	Approved, Investigational
Mianserin	The serum concentration of Mianserin can be decreased when it is combined with Mitotane.	Approved, Investigational
Mibefradil	The serum concentration of Mibefradil can be decreased when it is combined with Mitotane.	Investigational, Withdrawn
Miconazole	The serum concentration of Miconazole can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Mitotane.	Approved, Illicit
Midecamycin	The serum concentration of Midecamycin can be decreased when it is combined with Mitotane.	Approved
Midostaurin	The serum concentration of Midostaurin can be decreased when it is combined with Mitotane.	Approved, Investigational
Mifepristone	The serum concentration of Mifepristone can be decreased when it is combined with Mitotane.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Mitotane.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be decreased when it is combined with Mitotane.	Approved
Modafinil	The serum concentration of Modafinil can be decreased when it is combined with Mitotane.	Approved, Investigational
Mometasone	The serum concentration of Mometasone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Montelukast	The serum concentration of Montelukast can be decreased when it is combined with Mitotane.	Approved
Morphine	The serum concentration of Morphine can be decreased when it is combined with Mitotane.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitotane.	Approved, Investigational
Nabiximols	The serum concentration of Nabiximols can be decreased when it is combined with Mitotane.	Approved, Investigational
Naftopidil	The serum concentration of Naftopidil can be decreased when it is combined with Mitotane.	Investigational
Naloxegol	The serum concentration of Naloxegol can be decreased when it is combined with Mitotane.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Nateglinide	The serum concentration of Nateglinide can be decreased when it is combined with Mitotane.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be decreased when it is combined with Mitotane.	Investigational
Nefazodone	The serum concentration of Nefazodone can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Nelfinavir	The serum concentration of Nelfinavir can be decreased when it is combined with Mitotane.	Approved
Neratinib	The serum concentration of Neratinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Netupitant	The serum concentration of Netupitant can be decreased when it is combined with Mitotane.	Approved, Investigational
Nevirapine	The serum concentration of Nevirapine can be decreased when it is combined with Mitotane.	Approved
Nicardipine	The serum concentration of Nicardipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Nicotine	The serum concentration of Nicotine can be decreased when it is combined with Mitotane.	Approved
Nifedipine	The serum concentration of Nifedipine can be decreased when it is combined with Mitotane.	Approved
Niguldipine	The serum concentration of Niguldipine can be decreased when it is combined with Mitotane.	Experimental
Nilotinib	The serum concentration of Nilotinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Niludipine	The serum concentration of Niludipine can be decreased when it is combined with Mitotane.	Experimental
Nilvadipine	The serum concentration of Nilvadipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Nimesulide	The serum concentration of Nimesulide can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Nisoldipine	The serum concentration of Nisoldipine can be decreased when it is combined with Mitotane.	Approved
Nitrazepam	The serum concentration of Nitrazepam can be decreased when it is combined with Mitotane.	Approved
Nitrendipine	The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane.	Approved, Investigational
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Mitotane.	Approved
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Mitotane.	Approved
Nortriptyline	The serum concentration of Nortriptyline can be decreased when it is combined with Mitotane.	Approved
Nylidrin	The serum concentration of Nylidrin can be decreased when it is combined with Mitotane.	Approved
Odanacatib	The serum concentration of Odanacatib can be decreased when it is combined with Mitotane.	Investigational
Olaparib	The serum concentration of Olaparib can be decreased when it is combined with Mitotane.	Approved
Oleandrin	Oleandrin may decrease the cardiotoxic activities of Mitotane.	Experimental, Investigational
Oleoyl-estrone	The serum concentration of Oleoyl-estrone can be decreased when it is combined with Mitotane.	Investigational
Olopatadine	The serum concentration of Olopatadine can be decreased when it is combined with Mitotane.	Approved
Omeprazole	The serum concentration of Omeprazole can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Ondansetron	The serum concentration of Ondansetron can be decreased when it is combined with Mitotane.	Approved
Opium	The serum concentration of Opium can be decreased when it is combined with Mitotane.	Approved, Illicit
Orphenadrine	The serum concentration of Orphenadrine can be decreased when it is combined with Mitotane.	Approved
Osimertinib	The serum concentration of Osimertinib can be decreased when it is combined with Mitotane.	Approved
Ospemifene	The serum concentration of Ospemifene can be decreased when it is combined with Mitotane.	Approved, Investigational
Otilonium	The serum concentration of Otilonium can be decreased when it is combined with Mitotane.	Experimental, Investigational
Ouabain	Ouabain may decrease the cardiotoxic activities of Mitotane.	Approved
Oxazepam	The serum concentration of Oxazepam can be decreased when it is combined with Mitotane.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be decreased when it is combined with Mitotane.	Approved, Investigational
Oxycodone	The serum concentration of Oxycodone can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Oxymorphone	The serum concentration of Oxymorphone can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be decreased when it is combined with Mitotane.	Approved, Investigational
Palonosetron	The serum concentration of Palonosetron can be decreased when it is combined with Mitotane.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be decreased when it is combined with Mitotane.	Approved, Investigational
Pantoprazole	The serum concentration of Pantoprazole can be decreased when it is combined with Mitotane.	Approved
Paramethadione	The serum concentration of Paramethadione can be decreased when it is combined with Mitotane.	Approved
Paramethasone	The serum concentration of Paramethasone can be decreased when it is combined with Mitotane.	Approved
Parecoxib	The serum concentration of Parecoxib can be decreased when it is combined with Mitotane.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane.	Approved, Investigational
Paritaprevir	The serum concentration of Paritaprevir can be decreased when it is combined with Mitotane.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be decreased when it is combined with Mitotane.	Approved
Penfluridol	The serum concentration of Penfluridol can be decreased when it is combined with Mitotane.	Experimental
Pentamidine	The serum concentration of Pentamidine can be decreased when it is combined with Mitotane.	Approved, Investigational
Perampanel	The serum concentration of Perampanel can be decreased when it is combined with Mitotane.	Approved
Pergolide	The serum concentration of Pergolide can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved, Withdrawn
Perhexiline	The serum concentration of Perhexiline can be decreased when it is combined with Mitotane.	Approved, Investigational
Permethrin	The serum concentration of Permethrin can be decreased when it is combined with Mitotane.	Approved, Investigational
Perospirone	The serum concentration of Perospirone can be decreased when it is combined with Mitotane.	Approved
Perphenazine	The serum concentration of Perphenazine can be decreased when it is combined with Mitotane.	Approved
Peruvoside	Peruvoside may decrease the cardiotoxic activities of Mitotane.	Experimental
Pethidine	The serum concentration of Pethidine can be decreased when it is combined with Mitotane.	Approved
Phenacetin	The serum concentration of Phenacetin can be decreased when it is combined with Mitotane.	Withdrawn
Phenobarbital	The serum concentration of Phenobarbital can be increased when it is combined with Mitotane.	Approved, Investigational
Phenoxybenzamine	The serum concentration of Phenoxybenzamine can be decreased when it is combined with Mitotane.	Approved
Phenprocoumon	The serum concentration of Phenprocoumon can be decreased when it is combined with Mitotane.	Approved, Investigational
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Pilocarpine	The serum concentration of Pilocarpine can be decreased when it is combined with Mitotane.	Approved, Investigational
Pimecrolimus	The serum concentration of Pimecrolimus can be decreased when it is combined with Mitotane.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be decreased when it is combined with Mitotane.	Approved
Pinacidil	The serum concentration of Pinacidil can be decreased when it is combined with Mitotane.	Approved
Pinaverium	The serum concentration of Pinaverium can be decreased when it is combined with Mitotane.	Approved
Pioglitazone	The serum concentration of Pioglitazone can be decreased when it is combined with Mitotane.	Approved, Investigational
Piperaquine	The serum concentration of Piperaquine can be decreased when it is combined with Mitotane.	Approved, Investigational
Pipotiazine	The serum concentration of Pipotiazine can be decreased when it is combined with Mitotane.	Approved, Investigational
Pitolisant	The serum concentration of Pitolisant can be decreased when it is combined with Mitotane.	Approved, Investigational
Podofilox	The serum concentration of Podofilox can be decreased when it is combined with Mitotane.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Mitotane.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Posaconazole	The serum concentration of Posaconazole can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Prasterone	The serum concentration of Prasterone can be decreased when it is combined with Mitotane.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The serum concentration of Prasterone sulfate can be decreased when it is combined with Mitotane.	Investigational
Prasugrel	The serum concentration of Prasugrel can be decreased when it is combined with Mitotane.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Mitotane.	Approved
Prazepam	The serum concentration of Prazepam can be decreased when it is combined with Mitotane.	Approved, Illicit
Praziquantel	The serum concentration of Praziquantel can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Prednicarbate	The serum concentration of Prednicarbate can be decreased when it is combined with Mitotane.	Approved, Investigational
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Pregabalin	The serum concentration of Pregabalin can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Pregnenolone	The serum concentration of Pregnenolone can be decreased when it is combined with Mitotane.	Approved, Experimental, Investigational
Prenylamine	The serum concentration of Prenylamine can be decreased when it is combined with Mitotane.	Withdrawn
Primaquine	The serum concentration of Primaquine can be decreased when it is combined with Mitotane.	Approved
Prochlorperazine	The serum concentration of Prochlorperazine can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Proguanil	The serum concentration of Proguanil can be decreased when it is combined with Mitotane.	Approved
Promazine	The serum concentration of Promazine can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Propafenone	The serum concentration of Propafenone can be decreased when it is combined with Mitotane.	Approved
Propiverine	The serum concentration of Propiverine can be decreased when it is combined with Mitotane.	Approved, Investigational
Propofol	The serum concentration of Propofol can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Mitotane.	Approved, Investigational
Proscillaridin	Proscillaridin may decrease the cardiotoxic activities of Mitotane.	Experimental
Pyrazinamide	The serum concentration of Pyrazinamide can be decreased when it is combined with Mitotane.	Approved, Investigational
Quazepam	The serum concentration of Quazepam can be decreased when it is combined with Mitotane.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Mitotane.	Approved
Quinacrine	The serum concentration of Quinacrine can be decreased when it is combined with Mitotane.	Approved, Investigational
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Mitotane.	Approved, Investigational
Quinine	The serum concentration of Quinine can be decreased when it is combined with Mitotane.	Approved
Rabeprazole	The serum concentration of Rabeprazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Raloxifene	The serum concentration of Raloxifene can be decreased when it is combined with Mitotane.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be decreased when it is combined with Mitotane.	Approved, Investigational
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Mitotane.	Approved
Ranolazine	The serum concentration of Ranolazine can be decreased when it is combined with Mitotane.	Approved, Investigational
Reboxetine	The serum concentration of Reboxetine can be decreased when it is combined with Mitotane.	Approved, Investigational
Regorafenib	The serum concentration of Regorafenib can be decreased when it is combined with Mitotane.	Approved
Repaglinide	The serum concentration of Repaglinide can be decreased when it is combined with Mitotane.	Approved, Investigational
Retapamulin	The serum concentration of Retapamulin can be decreased when it is combined with Mitotane.	Approved
Ribociclib	The serum concentration of Ribociclib can be decreased when it is combined with Mitotane.	Approved, Investigational
Rifabutin	The serum concentration of Rifabutin can be decreased when it is combined with Mitotane.	Approved, Investigational
Rifampicin	The serum concentration of Rifampicin can be decreased when it is combined with Mitotane.	Approved
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Mitotane.	Approved
Rimexolone	The serum concentration of Rimexolone can be decreased when it is combined with Mitotane.	Approved
Rimonabant	The serum concentration of Rimonabant can be decreased when it is combined with Mitotane.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Mitotane.	Approved
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Mitotane.	Approved, Investigational
Ritonavir	The serum concentration of Ritonavir can be decreased when it is combined with Mitotane.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be decreased when it is combined with Mitotane.	Approved
Rofecoxib	The serum concentration of Rofecoxib can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Roflumilast	The serum concentration of Roflumilast can be decreased when it is combined with Mitotane.	Approved
Rolapitant	The serum concentration of Rolapitant can be decreased when it is combined with Mitotane.	Approved, Investigational
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Mitotane.	Approved, Investigational
Ropinirole	The serum concentration of Ropinirole can be decreased when it is combined with Mitotane.	Approved, Investigational
Ropivacaine	The serum concentration of Ropivacaine can be decreased when it is combined with Mitotane.	Approved
Rosiglitazone	The serum concentration of Rosiglitazone can be decreased when it is combined with Mitotane.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be decreased when it is combined with Mitotane.	Approved
Rotigotine	The serum concentration of Rotigotine can be decreased when it is combined with Mitotane.	Approved
Roxithromycin	The serum concentration of Roxithromycin can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Rucaparib	The serum concentration of Rucaparib can be decreased when it is combined with Mitotane.	Approved, Investigational
Rupatadine	The serum concentration of Rupatadine can be decreased when it is combined with Mitotane.	Approved
Ruxolitinib	The serum concentration of Ruxolitinib can be decreased when it is combined with Mitotane.	Approved
Safinamide	The serum concentration of Safinamide can be decreased when it is combined with Mitotane.	Approved, Investigational
Salmeterol	The serum concentration of Salmeterol can be decreased when it is combined with Mitotane.	Approved
Saquinavir	The serum concentration of Saquinavir can be decreased when it is combined with Mitotane.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Mitotane.	Approved
Selegiline	The serum concentration of Selegiline can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Seletracetam	The serum concentration of Seletracetam can be decreased when it is combined with Mitotane.	Investigational
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Mitotane.	Approved
Seratrodast	The serum concentration of Seratrodast can be decreased when it is combined with Mitotane.	Approved
Sertindole	The serum concentration of Sertindole can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Sertraline	The serum concentration of Sertraline can be decreased when it is combined with Mitotane.	Approved
Sevoflurane	The serum concentration of Sevoflurane can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Sibutramine	The serum concentration of Sibutramine can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be decreased when it is combined with Mitotane.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be decreased when it is combined with Mitotane.	Approved
Simeprevir	The serum concentration of Simeprevir can be decreased when it is combined with Mitotane.	Approved
Simvastatin	The serum concentration of Simvastatin can be decreased when it is combined with Mitotane.	Approved
Sirolimus	The serum concentration of Sirolimus can be decreased when it is combined with Mitotane.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be decreased when it is combined with Mitotane.	Approved, Investigational
Solifenacin	The serum concentration of Solifenacin can be decreased when it is combined with Mitotane.	Approved
Sonidegib	The serum concentration of Sonidegib can be decreased when it is combined with Mitotane.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be decreased when it is combined with Mitotane.	Approved, Investigational
Spiramycin	The serum concentration of Spiramycin can be decreased when it is combined with Mitotane.	Approved
Spironolactone	The therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone.	Approved
Sufentanil	The serum concentration of Sufentanil can be decreased when it is combined with Mitotane.	Approved, Investigational
Sulfadiazine	The serum concentration of Sulfadiazine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The serum concentration of Sulfamethoxazole can be decreased when it is combined with Mitotane.	Approved
Sulfinpyrazone	The serum concentration of Sulfinpyrazone can be decreased when it is combined with Mitotane.	Approved
Sumatriptan	The serum concentration of Sumatriptan can be increased when it is combined with Mitotane.	Approved, Investigational
Sunitinib	The serum concentration of Sunitinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be decreased when it is combined with Mitotane.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Mitotane.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Mitotane.	Approved
Tacrolimus	The serum concentration of Tacrolimus can be decreased when it is combined with Mitotane.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be decreased when it is combined with Mitotane.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Mitotane.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be decreased when it is combined with Mitotane.	Approved, Investigational
Tasimelteon	The serum concentration of Tasimelteon can be decreased when it is combined with Mitotane.	Approved, Investigational
Tasosartan	The serum concentration of Tasosartan can be decreased when it is combined with Mitotane.	Approved
Taurochenodeoxycholic acid	The serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Mitotane.	Experimental
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Telithromycin	The serum concentration of Telithromycin can be decreased when it is combined with Mitotane.	Approved
Temazepam	The serum concentration of Temazepam can be decreased when it is combined with Mitotane.	Approved, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Mitotane.	Approved
Teniposide	The serum concentration of Teniposide can be decreased when it is combined with Mitotane.	Approved
Terbinafine	The serum concentration of Terbinafine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of Terfenadine can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Terodiline	The serum concentration of Terodiline can be decreased when it is combined with Mitotane.	Experimental
Tesmilifene	The serum concentration of Tesmilifene can be decreased when it is combined with Mitotane.	Investigational
Testosterone	The serum concentration of Testosterone can be decreased when it is combined with Mitotane.	Approved, Investigational
Testosterone cypionate	The serum concentration of Testosterone cypionate can be decreased when it is combined with Mitotane.	Approved
Testosterone enanthate	The serum concentration of Testosterone enanthate can be decreased when it is combined with Mitotane.	Approved
Testosterone propionate	The serum concentration of Testosterone propionate can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The serum concentration of Testosterone undecanoate can be decreased when it is combined with Mitotane.	Approved, Investigational
Tetracycline	The serum concentration of Tetracycline can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Tetrahydropalmatine	The serum concentration of Tetrahydropalmatine can be decreased when it is combined with Mitotane.	Investigational
Tetrandrine	The serum concentration of Tetrandrine can be decreased when it is combined with Mitotane.	Experimental
Tezacaftor	The serum concentration of Tezacaftor can be decreased when it is combined with Mitotane.	Approved, Investigational
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Mitotane.	Approved
Thiotepa	The serum concentration of Thiotepa can be decreased when it is combined with Mitotane.	Approved, Investigational
Tiagabine	The serum concentration of Tiagabine can be decreased when it is combined with Mitotane.	Approved, Investigational
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Mitotane.	Approved
Ticlopidine	The serum concentration of Ticlopidine can be decreased when it is combined with Mitotane.	Approved
Tinidazole	The serum concentration of Tinidazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Tiotropium	The serum concentration of Tiotropium can be decreased when it is combined with Mitotane.	Approved
Tipranavir	The serum concentration of Tipranavir can be decreased when it is combined with Mitotane.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be decreased when it is combined with Mitotane.	Approved, Withdrawn
Tocofersolan	The serum concentration of Tocofersolan can be decreased when it is combined with Mitotane.	Approved
Tocopherol	The serum concentration of Tocopherol can be decreased when it is combined with Mitotane.	Approved, Investigational
Tofacitinib	The serum concentration of Tofacitinib can be decreased when it is combined with Mitotane.	Approved, Investigational
Tolfenamic Acid	The serum concentration of Tolfenamic Acid can be decreased when it is combined with Mitotane.	Approved, Investigational
Tolterodine	The serum concentration of Tolterodine can be decreased when it is combined with Mitotane.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Mitotane.	Approved
Topiramate	The serum concentration of Topiramate can be increased when it is combined with Mitotane.	Approved
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Mitotane.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be decreased when it is combined with Mitotane.	Approved, Investigational
Tramadol	The serum concentration of Tramadol can be decreased when it is combined with Mitotane.	Approved, Investigational
Tranilast	The serum concentration of Tranilast can be decreased when it is combined with Mitotane.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Mitotane.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Mitotane.	Approved, Investigational
Trazodone	The serum concentration of Trazodone can be decreased when it is combined with Mitotane.	Approved, Investigational
Tretinoin	The serum concentration of Tretinoin can be decreased when it is combined with Mitotane.	Approved, Investigational, Nutraceutical
Triamcinolone	The serum concentration of Triamcinolone can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be decreased when it is combined with Mitotane.	Approved, Investigational
Trimebutine	The serum concentration of Trimebutine can be decreased when it is combined with Mitotane.	Approved
Trimethadione	The serum concentration of Trimethadione can be decreased when it is combined with Mitotane.	Approved
Trimethoprim	The serum concentration of Trimethoprim can be decreased when it is combined with Mitotane.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be decreased when it is combined with Mitotane.	Approved
Troglitazone	The serum concentration of Troglitazone can be decreased when it is combined with Mitotane.	Investigational, Withdrawn
Troleandomycin	The serum concentration of Troleandomycin can be decreased when it is combined with Mitotane.	Approved
Udenafil	The serum concentration of Udenafil can be decreased when it is combined with Mitotane.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Mitotane.	Approved
Ulobetasol	The serum concentration of Ulobetasol can be decreased when it is combined with Mitotane.	Approved
Valbenazine	The serum concentration of Valbenazine can be decreased when it is combined with Mitotane.	Approved, Investigational
Valdecoxib	The serum concentration of Valdecoxib can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Mitotane.	Approved, Investigational
Vandetanib	The serum concentration of Vandetanib can be decreased when it is combined with Mitotane.	Approved
Vanoxerine	The serum concentration of Vanoxerine can be decreased when it is combined with Mitotane.	Investigational
Vardenafil	The serum concentration of Vardenafil can be decreased when it is combined with Mitotane.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Mitotane.	Approved
Velpatasvir	The serum concentration of Velpatasvir can be decreased when it is combined with Mitotane.	Approved, Investigational
Vemurafenib	The serum concentration of Vemurafenib can be decreased when it is combined with Mitotane.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Mitotane.	Approved, Investigational
Venlafaxine	The serum concentration of Venlafaxine can be decreased when it is combined with Mitotane.	Approved
Verapamil	The serum concentration of Verapamil can be decreased when it is combined with Mitotane.	Approved
Vicriviroc	The serum concentration of Vicriviroc can be decreased when it is combined with Mitotane.	Investigational
Vilanterol	The serum concentration of Vilanterol can be decreased when it is combined with Mitotane.	Approved
Vilazodone	The serum concentration of Vilazodone can be decreased when it is combined with Mitotane.	Approved
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Mitotane.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Mitotane.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be decreased when it is combined with Mitotane.	Approved, Investigational
Vinflunine	The serum concentration of Vinflunine can be decreased when it is combined with Mitotane.	Approved, Investigational
Vinorelbine	The serum concentration of Vinorelbine can be decreased when it is combined with Mitotane.	Approved, Investigational
Vinpocetine	The serum concentration of Vinpocetine can be decreased when it is combined with Mitotane.	Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Mitotane.	Approved, Investigational
Vorapaxar	The serum concentration of Vorapaxar can be decreased when it is combined with Mitotane.	Approved
Voriconazole	The serum concentration of Voriconazole can be decreased when it is combined with Mitotane.	Approved, Investigational
Vortioxetine	The serum concentration of Vortioxetine can be decreased when it is combined with Mitotane.	Approved, Investigational
Voxilaprevir	The serum concentration of Voxilaprevir can be decreased when it is combined with Mitotane.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Mitotane.	Approved
WIN 55212-2	The serum concentration of WIN 55212-2 can be decreased when it is combined with Mitotane.	Experimental
Yohimbine	The serum concentration of Yohimbine can be decreased when it is combined with Mitotane.	Approved, Investigational, Vet Approved
Zafirlukast	The serum concentration of Zafirlukast can be decreased when it is combined with Mitotane.	Approved, Investigational
Zalcitabine	The serum concentration of Zalcitabine can be decreased when it is combined with Mitotane.	Approved, Investigational
Zaleplon	The serum concentration of Zaleplon can be decreased when it is combined with Mitotane.	Approved, Illicit, Investigational
Ziconotide	The serum concentration of Ziconotide can be decreased when it is combined with Mitotane.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Mitotane.	Approved
Zileuton	The serum concentration of Zileuton can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Ziprasidone	The serum concentration of Ziprasidone can be decreased when it is combined with Mitotane.	Approved
Zolpidem	The serum concentration of Zolpidem can be decreased when it is combined with Mitotane.	Approved
Zomepirac	The serum concentration of Zomepirac can be decreased when it is combined with Mitotane.	Withdrawn
Zonisamide	The serum concentration of Zonisamide can be decreased when it is combined with Mitotane.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be decreased when it is combined with Mitotane.	Approved
Zotepine	The serum concentration of Zotepine can be decreased when it is combined with Mitotane.	Approved, Investigational, Withdrawn
Zuclopenthixol	The serum concentration of Zuclopenthixol can be decreased when it is combined with Mitotane.	Approved, Investigational

Food Interactions

• Take without regard to meals.

References

General References

Not Available

External Links

Human Metabolome Database

HMDB0014786

KEGG Drug

D00420

PubChem Compound

4211

PubChem Substance

46508319

ChemSpider

4066

ChEBI

6954

ChEMBL

CHEMBL1670

Therapeutic Targets Database

DAP000033

PharmGKB

PA164746157

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Mitotane

ATC Codes

L01XX23 — Mitotane

• L01XX — Other antineoplastic agents
• L01X — OTHER ANTINEOPLASTIC AGENTS
• L01 — ANTINEOPLASTIC AGENTS
• L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

AHFS Codes

• 10:00.00 — Antineoplastic Agents

MSDS

Download (57 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Prostate Cancer	1
2	Terminated	Treatment	Recurrent Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma	1
3	Active Not Recruiting	Treatment	Stage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma	1
3	Completed	Treatment	Carcinoma, Adrenal Cortical	1
3	Not Yet Recruiting	Treatment	ENSAT Stage I Adrenal Cortex Carcinoma / ENSAT Stage II Adrenal Cortex Carcinoma / ENSAT Stage III Adrenal Cortex Carcinoma	1
3	Unknown Status	Treatment	Adrenocortical Carcinoma	1

Pharmacoeconomics

Manufacturers

• Bristol myers squibb

Packagers

• B&B Pharmaceuticals
• Bristol-Myers Squibb Co.
• Mead Johnson and Co.

Dosage forms

Form	Route	Strength
Tablet	Oral	500 mg
Tablet	Oral	500 mg/1

Prices

Unit description	Cost	Unit
Mitotane powder	7.75USD	g
Lysodren 500 mg tablet	5.13USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	77 °C	PhysProp
water solubility	0.1 mg/L (at 25 °C)	BIGGAR,JW & RIGGS,RI (1974)
logP	6	Not Available
logS	-6.51	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	9.42e-06 mg/mL	ALOGPS
logP	6.08	ALOGPS
logP	6.11	ChemAxon
logS	-7.5	ALOGPS
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	0	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	0 Å2	ChemAxon
Rotatable Bond Count	3	ChemAxon
Refractivity	79.97 m3·mol-1	ChemAxon
Polarizability	29.93 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9942
Blood Brain Barrier	+	0.9905
Caco-2 permeable	+	0.8815
P-glycoprotein substrate	Non-substrate	0.8053
P-glycoprotein inhibitor I	Non-inhibitor	0.9004
P-glycoprotein inhibitor II	Non-inhibitor	0.988
Renal organic cation transporter	Non-inhibitor	0.7959
CYP450 2C9 substrate	Non-substrate	0.7899
CYP450 2D6 substrate	Non-substrate	0.818
CYP450 3A4 substrate	Non-substrate	0.7045
CYP450 1A2 substrate	Inhibitor	0.9542
CYP450 2C9 inhibitor	Inhibitor	0.7241
CYP450 2D6 inhibitor	Non-inhibitor	0.9349
CYP450 2C19 inhibitor	Inhibitor	0.8993
CYP450 3A4 inhibitor	Non-inhibitor	0.8629
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.8
Ames test	Non AMES toxic	0.9751
Carcinogenicity	Non-carcinogens	0.575
Biodegradation	Not ready biodegradable	0.9596
Rat acute toxicity	2.1911 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9221
hERG inhibition (predictor II)	Non-inhibitor	0.875

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (8.84 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
GC-MS Spectrum - GC-EI-Q	GC-MS	splash10-000i-2590000000-2d3f8090ffa4733bf9ee
Mass Spectrum (Electron Ionization)	MS	splash10-000i-2690000000-770065ddc57899130a31
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
1H NMR Spectrum	1D NMR	Not Applicable
13C NMR Spectrum	1D NMR	Not Applicable

Taxonomy

Description

This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Diphenylmethanes

Direct Parent

Diphenylmethanes

Alternative Parents

Chlorobenzenes / Aryl chlorides / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides

Substituents

Diphenylmethane / Halobenzene / Chlorobenzene / Aryl halide / Aryl chloride / Hydrocarbon derivative / Organochloride / Organohalogen compound / Alkyl halide / Alkyl chloride

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

Not Available

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:23